AGIOS PHARMACEUTICALS
Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.
AGIOS PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2008-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.agios.com
Total Employee:
101+
Status:
Active
Contact:
+1 617 649 8600
Email Addresses:
[email protected]
Total Funding:
775.82 M USD
Technology used in webpage:
Apple Mobile Web Clips Icon HSTS IPv6 ReCAPTCHA Cloudflare Hosting ReCAPTCHA V2 Microsoft HSTS IncludeSubdomains PreLoad Ruby On Rails Token DigiCert SSL
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Fovea Pharmaceuticals
Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Quest PharmaTech
Quest PharmaTech is a pharmaceutical company that is developing antibody-based immunotherapeutic products for cancer.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Vion Pharmaceuticals Inc
Vion Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes cancer treatment technologies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Celgene
Celgene investment in Series C - Agios Pharmaceuticals
Flagship Pioneering
Flagship Pioneering investment in Series C - Agios Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Series C - Agios Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series C - Agios Pharmaceuticals
Celgene
Celgene investment in Series B - Agios Pharmaceuticals
Flagship Pioneering
Flagship Pioneering investment in Series A - Agios Pharmaceuticals
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Agios Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series A - Agios Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-06 | Agios Appoints Tsveta Milanova as Chief Commercial Officer |
| 2022-07-13 | Agios appoints Brian Goff as new CEO |
Official Site Inspections
http://www.agios.com Semrush global rank: 2.93 M Semrush visits lastest month: 5.44 K
- Host name: 83.162.211.130.bc.googleusercontent.com
- IP address: 130.211.162.83
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Agios Pharmaceuticals"
Agios Announces Evolution of Research Organization
May 16, 2022 Such forward-looking statements include those regarding Agios’ plans, strategies and expectations for the preclinical, clinical and commercial advancement of its drug …See details»
Agios Pharmaceuticals - Wikipedia
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for …See details»
Agios Pharmaceuticals - LinkedIn
Agios is a biopharmaceutical company that is fueled by connections. We are passionately committed to applying our leadership in the field of cellular metabolism to create life-changing therapies ...See details»
Agios Announces Evolution of Research Organization
May 16, 2022 Agios plans to reduce up to 50 roles focused on exploratory research, while retaining a strong internal research team focused on roles critical to advancing the company’s …See details»
About Us – Agios
Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism. This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to pioneering new …See details»
Agios Announces New Commercial Leadership Structure
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic …See details»
Agios Pharmaceuticals - Organisation Profile - Lix
Agios is a biopharmaceutical company that is fueled by connections. We are passionately committed to applying our leadership in the field of cellular metabolism to create life-changing …See details»
Agios Pharmaceuticals - businessabc
Jun 12, 2025 Agios Pharmaceuticals was founded in 2007 and made its debut on the NASDAQ in July 2013. Its research and development program has advanced rapidly, and the company …See details»
Agios Pharmaceuticals Mission, Benefits, and Work …
Come see what’s going on inside Agios Pharmaceuticals, including the company culture, employee work-life benefits, and business goals. Discover all the key insights that make people want to work here. Read about the office locations, …See details»
Corporate Governance – Agios Pharmaceuticals, Inc.
The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Leadership – Agios
At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life …See details»
Values – Agios
At Agios, our shared values and community-centric culture cultivate an environment that promotes collaboration, contribution, engagement and high regard for others’ points of view.See details»
Culture – Agios
At Agios, this deep sense of caring is what drives every person on our team and enables us to do meaningful work on behalf of people with rare diseases. It is central to our people …See details»
Pipeline – Agios
Agios has a proven track record of leveraging our expertise in cellular metabolism to develop new therapies and bring innovative medicines to patients in need. Building on our core capabilities, …See details»
Corporate Social Responsibility – Agios
It codifies Agios’s commitment to doing business in an ethical manner and in compliance with all applicable laws, regulations and industry standards. The Code helps guide our daily …See details»
Welcome to myAgios Patient Support Services
Welcome to myAgios Patient Support Services, a custom support program for people living with pyruvate kinase (PK) deficiency and those prescribed PYRUKYND® (mitapivat). Please see …See details»
Servier to Acquire Agios Pharmaceuticals’ Oncology Business
“The strategic acquisition of Agios’ oncology business, including its precision medicine portfolio and pipeline, is aligned with our ambition to become a recognized player in oncology and …See details»
Agios Reports Second Quarter 2025 Financial Results and Provides ...
1 day ago Conference Call Information Agios will host a conference call and live webcast today at 8:00 a.m. ET to discuss the company’s second quarter 2025 financial results and recent …See details»
Earnings call transcript: Agios Pharm Q2 2025 earnings miss EPS, …
1 day ago Agios Pharmaceuticals reported its Q2 2025 earnings, revealing a larger-than-expected loss per share and a notable revenue beat. The company posted an EPS of -$1.93, …See details»
Agios Announces Key 2025 Milestones for Innovative Rare Disease ...
Jan 13, 2025 The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.See details»